UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): June 11, 2015

TONIX PHARMACEUTICALS HOLDING CORP.

(Exact name of registrant as specified in its charter)

509 Madison Avenue, Suite 306, New York, New York 10022

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (212) 980-9155

Copy of correspondence to:

Marc J. Ross, Esq.

James M. Turner, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway

New York, New York 10006

Tel: (212) 930-9700 Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On June 11, 2015, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced additional data from its Phase 2b BESTFIT (Bedtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy) study presented in two posters entitled “TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization” and “TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement” (collectively, the “Posters”) at the 16^th Annual European Congress of Rheumatology, to be hosted by the European League Against Rheumatism.  The Posters were presented by Dr. Seth Lederman, M.D., President and Chief Executive Officer of the Company and Dr. R. Michael Gendreau, M.D., Ph.D., Principal of Gendreau Consulting and a member of the Company’s scientific advisory board.

The foregoing description of the Posters is qualified in its entirety by reference to the Posters, copies of which are filed as Exhibits 99.01 and 99.02 to, and are incorporated by reference in, this report.

On June 11, 2015, the Company issued a press release announcing the presentation of additional data from the Phase 2b BESTFIT study through the Posters. A copy of the press release that discusses this matter is filed as Exhibit 99.03 to, and incorporated by reference in, this report.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.